References for appendices J – S

National Clinical Guideline Centre (UK)

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.

National Clinical Guideline Centre (UK). Psoriasis: Assessment and Management of Psoriasis. London: Royal College of Physicians (UK); 2012 Oct. (NICE Clinical Guidelines, No. 153.)

See 2019 Partial Update

Update information September 2017: The guideline has been revised throughout to link to MHRA advice and NICE technology appraisals that have been completed since original publication. Minor updates since publication August 2019: Links to the MHRA safety advice on the risk of using retinoids in pregnancy have been updated to the June 2019 version.

Update information September 2017: The guideline has been revised throughout to link to MHRA advice and NICE technology appraisals that have been completed since original publication. Minor updates since publication August 2019: Links to the MHRA safety advice on the risk of using retinoids in pregnancy have been updated to the June 2019 version.

Psoriasis: Assessment and Management of Psoriasis.

Show details

Contents

< PrevNext >

Appendix UReferences for appendices J – S

1.: Oranje AP, Marcoux D, Svensson A, Prendiville J, Krafchik B, Toole J, et al. Topical calcipotriol in childhood psoriasis. Journal of the American Academy of Dermatology. 1997;36(2:Pt 1):203–208. [PubMed: 9039169]
2.: Molin L, Cutler TP, Helander I, Nyfors B, Downes N. Comparative efficacy of calcipotriol (MC903) cream and betamethasone 17-valerate cream in the treatment of chronic plaque psoriasis. A randomized, double-blind, parallel group multicentre study. Calcipotriol Study Group. British Journal of Dermatology. 1997;136(1):89–93. [PubMed: 9039301]
3.: Kragballe K, Gjertsen BT, de HD, Karlsmark T, van de Kerkhof PC, Larko O, et al. Double-blind, right/left comparison of calcipotriol and betamethasone valerate in treatment of psoriasis vulgaris. Lancet. 1991;337(8735):193–196. [PubMed: 1670840]
4.: Highton A, Quell J. Calcipotriene ointment 0.005% for psoriasis: a safety and efficacy study. Calcipotriene Study Group. Journal of the American Academy of Dermatology. 1995;32(1):67–72. [PubMed: 7822519]
5.: Dubertret L, Wallach D, Souteyrand P, Perussel M, Kalis B, Meynadier J, et al. Efficacy and safety of calcipotriol (MC 903) ointment in psoriasis vulgaris. A randomized, double-blind, right/left comparative, vehicle-controlled study. Journal of the American Academy of Dermatology. 1992;27(6 Pt 1):983–988. [PubMed: 1479106]
6.: Harrington CI, Goldin D, Lovell CR, van de Kerkhof P, Nieboer C, Austad J, et al. Comparative effects of two different calcipotriol (MC 903) cream formulations versus placebo in psoriasis vulgaris. A randomised, double-blind, placebo-controlled, parallel group multi-centre study 1. Journal of the European Academy of Dermatology and Venereology. 1996;6(2):152–158.
7.: Langley RG, Gupta A, Papp K, Wexler D, Osterdal ML, Curcic D. Calcipotriol plus betamethasone dipropionate gel compared with tacalcitol ointment and the gel vehicle alone in patients with psoriasis vulgaris: a randomized, controlled clinical trial. Dermatology. 2011;222(2):148–156. [PubMed: 21293107]
8.: Medansky RS, Brody NI, Kanof NB, Russo GJ, Peets EA. Clinical investigations of mometasone furoate - a novel nonfluorinated, topical corticosteroid. Seminars in Dermatology. 1987;6(2):94–100.
9.: Sears HW. A double-blind, randomized, placebo-controlled evaluation of the efficacy and safety of hydrocortisone buteprate 0.1% cream in the treatment of psoriasis. Advances in Therapy. 1997;14(3):140–149.
10.: Katz HI, Prawer SE, Medansky RS, Krueger GG, Mooney JJ, Jones ML, et al. Intermittent corticosteroid maintenance treatment of psoriasis: a double-blind multicenter trial of augmented betamethasone dipropionate ointment in a pulse dose treatment regimen. Dermatologica. 1991;183(4):269–274. [PubMed: 1809589]
11.: Weinstein GD, Krueger GG, Lowe NJ, Duvic M, Friedman DJ, Jegasothy BV, et al. Tazarotene gel, a new retinoid, for topical therapy of psoriasis: vehicle-controlled study of safety, efficacy, and duration of therapeutic effect. Journal of the American Academy of Dermatology. 1997;37(1):85–92. [PubMed: 9216528]
12.: Weinstein GD. Safety, efficacy and duration of therapeutic effect of tazarotene used in the treatment of plaque psoriasis. British Journal of Dermatology. 1996;135(Suppl 49):32–36. [PubMed: 9035703]
13.: Gottlieb AB, Ford RO, Spellman MC. The efficacy and tolerability of clobetasol propionate foam 0.05% in the treatment of mild to moderate plaque-type psoriasis of nonscalp regions. Journal of Cutaneous Medicine and Surgery. 2003;7(3):185–192. [PubMed: 12704534]
14.: Berth-Jones J, Chu AC, Dodd WA, Ganpule M, Griffiths WA, Haydey RP, et al. A multicentre, parallel-group comparison of calcipotriol ointment and short-contact dithranol therapy in chronic plaque psoriasis. British Journal of Dermatology. 1992;127(3):266–271. [PubMed: 1390171]
15.: Alora-Palli MB, Perkins AC, Van Cott A, Kimball AB. Efficacy and tolerability of a cosmetically acceptable coal tar solution in the treatment of moderate plaque psoriasis: a controlled comparison with calcipotriene (calcipotriol) cream. American Journal of Clinical Dermatology. 2010;11(4):275–283. [PubMed: 20513160]
16.: Pinheiro N. Comparative effects of calcipotriol ointment (50 micrograms/g) and 5% coal tar/2% allantoin/0.5% hydrocortisone cream in treating plaque psoriasis. British Journal of Clinical Practice. 1997;51(1):16–19. [PubMed: 9158266]
17.: Barker JN, Ashton RE, Marks R, Harris RI, Berth-Jones J. Topical maxacalcitol for the treatment of psoriasis vulgaris: a placebo-controlled, double-blind, dose-finding study with active comparator. British Journal of Dermatology. 1999;141(2):274–278. [PubMed: 10468799]
18.: Barker JN, Griffiths CE. Combination therapy for psoriasis. Dermatologic Therapy. 1999;11:96–103.
19.: Perez A, Chen TC, Turner A, Raab R, Bhawan J, Poche P, et al. Efficacy and safety of topical calcitriol (1,25-dihydroxyvitamin d3) for the treatment of psoriasis. British Journal of Dermatology. 1996;134(2):238–246. [PubMed: 8746336]
20.: Fleming C, Ganslandt C, Guenther L, Johannesson A, Buckley C, Simon JC, et al. Calcipotriol plus betamethasone dipropionate gel compared with its active components in the same vehicle and the vehicle alone in the treatment of psoriasis vulgaris: a randomised, parallel group, double-blind, exploratory study. European Journal of Dermatology. 2010;20(4):465–471. [PubMed: 20413372]
21.: Kaufmann R, Bibby A, Bissonnette R, Cambazard F, Chu A, Decroix J, et al. A new calcipotriol/betamethasone dipropionate formulation (DaivobetTM) is an fffective once-daily treatment for psoriasis vulgaris. Dermatology. 2002;205(4):389–393. [PubMed: 12444337]
22.: Decroix J, Pres H, Tsankov N, Poncet M, Arsonnaud S. Clobetasol propionate lotion in the treatment of moderate to severe plaque-type psoriasis. Cutis. 2004;74(3):201–206. [PubMed: 15499763]
23.: Weinstein GD, Koo JY, Krueger GG, Lebwohl MG, Lowe NJ, Menter MA, et al. Tazarotene cream in the treatment of psoriasis: Two multicenter, double-blind, randomized, vehicle-controlled studies of the safety and efficacy of tazarotene creams 0.05% and 0.1% applied once daily for 12 weeks. Journal of the American Academy of Dermatology. 2003;48(5):760–767. [PubMed: 12734506]
24.: Langner A, Verjans H, Stapor V, Mol M, Fraczykowska M. 1alpha, 25-Dihydroxyvitamin D₃ (calcitriol) ointment in psoriasis. Journal of Dermatological Treatment. 1992;3(4):177–180.
25.: Langner A, Verjans H, Stapor V, Mol M, Fraczykowska M. Topical calcitriol in the treatment of chronic plaque psoriasis: a double-blind study. British Journal of Dermatology. 1993;128(5):566–571. [PubMed: 8504051]
26.: Papp KA, Guenther L, Boyden B, Larsen FG, Harvima RJ, Guilhou JJ, et al. Early onset of action and efficacy of a combination of calcipotriene and betamethasone dipropionate in the treatment of psoriasis. Journal of the American Academy of Dermatology. 2003;48(1):48–54. [PubMed: 12522370]
27.: Guenther L, van de Kerkhof PC, Snellman E, Kragballe K, Chu AC, Tegner E, et al. Efficacy and safety of a new combination of calcipotriol and betamethasone dipropionate (once or twice daily) compared to calcipotriol (twice daily) in the treatment of psoriasis vulgaris: a randomized, double-blind, vehicle-controlled clinical trial. British Journal of Dermatology. 2002;147(2):316–323. [PubMed: 12174105]
28.: Wortzel WH. A new corticosteroid for moderate/severe dermatoses. Clinical Medicine. 1975;82(3):23–26.
29.: Lowe N, Feldman SR, Sherer D, Weiss J, Shavin JS, Lin YL, et al. Clobetasol propionate lotion, an efficient and safe alternative to clobetasol propionate emollient cream in subjects with moderate to severe plaque-type psoriasis. Journal of Dermatological Treatment. 2005;16(3):158–164. [PubMed: 16096182]
30.: Gottlieb A, Chaudhari U, Baker D, Perate M, Dooley LT. The National Psoriasis Foundation Psoriasis Score (NPF-PS) system versus the Psoriasis Area Severity Index (PASI) and Physician’s Global Assessment (PGA): a comparison. Journal of Drugs in Dermatology: JDD. 2003;2(3):260–266. [PubMed: 12848110]
31.: Lebwohl M, Sherer D, Washenik K, Krueger GG, Menter A, Koo J, et al. A randomized, double-blind, placebo-controlled study of clobetasol propionate 0.05% foam in the treatment of nonscalp psoriasis. International Journal of Dermatology. 2002;41(5):269–274. [PubMed: 12100701]
32.: Jarratt MT, Clark SD, Savin RC, Swinyer LJ, Safley CF, Brodell RT, et al. Evaluation of the efficacy and safety of clobetasol propionate spray in the treatment of plaque-type psoriasis. Cutis. 2006;78(5):348–354. [PubMed: 17186795]
33.: Kragballe K, Barnes L, Hamberg KJ, Hutchinson P, Murphy F, Moller S, et al. Calcipotriol cream with or without concurrent topical corticosteroid in psoriasis: tolerability and efficacy. British Journal of Dermatology. 1998;139(4):649–654. [PubMed: 9892908]
34.: Ortonne P, Kaufmann R, Lecha M, Goodfield M. Efficacy of treatment with calcipotriol/betamethasone dipropionate followed by calcipotriol alone compared with tacalcitol for the treatment of psoriasis vulgaris: a randomised, double-blind trial. Dermatology. 2004;209(4):308–313. [PubMed: 15539894]
35.: Camarasa JM, Ortonne JP, Dubertret L. Calcitriol shows greater persistence of treatment effect than betamethasone dipropionate in topical psoriasis therapy. Journal of Dermatological Treatment. 2003;14(1):8–13. [PubMed: 12745849]
36.: Molin L. Does addition of topical calcipotriol to UVB increase the risk of irritant reactions in psoriasis? The Calcipotriol-UVB Study Group. Acta Dermato-Venereologica. 1997;77(5):401–402. [PubMed: 9298141]
37.: Cunliffe WJ, Berth-Jones J, Claudy A, Fairiss G, Goldin D, Gratton D, et al. Comparative study of calcipotriol (MC 903) ointment and betamethasone 17-valerate ointment in patients with psoriasis vulgaris. Journal of the American Academy of Dermatology. 1992;26(5 Pt 1):736–743. [PubMed: 1583173]
38.: Douglas WS, Poulin Y, Decroix J, Ortonne JP, Mrowietz U, Gulliver W, et al. A new calcipotriol/betamethasone formulation with rapid onset of action was superior to monotherapy with betamethasone dipropionate or calcipotriol in psoriasis vulgaris. Acta Dermato-Venereologica. 2002;82(2):131–135. [PubMed: 12125943]
39.: Ruzicka T, Lorenz B. Comparison of calcipotriol monotherapy and a combination of calcipotriol and betamethasone valerate after 2 weeks’ treatment with calcipotriol in the topical therapy of psoriasis vulgaris: a multicentre, double-blind, randomized study. British Journal of Dermatology. 1998;138(2):254–258. [PubMed: 9602870]
40.: Tham SN, Lun KC, Cheong WK. A comparative study of calcipotriol ointment and tar in chronic plaque psoriasis. British Journal of Dermatology. 1994;131(5):673–677. [PubMed: 7999599]
41.: Hutchinson P, Marks R, White J. The efficacy, safety and tolerance of calcitriol 3 microg/g ointment in the treatment of plaque psoriasis: a comparison with short-contact dithranol. Dermatology. 2000;201(2):139–145. [PubMed: 11053917]
42.: Wall AR, Poyner TF, Menday AP. A comparison of treatment with dithranol and calcipotriol on the clinical severity and quality of life in patients with psoriasis. British Journal of Dermatology. 1998;139(6):1005–1011. [PubMed: 9990363]
43.: Christensen OB, Mork N-J, Ashton R, Daniel F, Anehus S. Comparison of a treatment phase and a follow-up phase of short-contact dithranol and calcipotriol in outpatients with chronic plaque psoriasis. Journal of Dermatological Treatment. 1999;10(4):261–265.
44.: Menter A, Abramovits W, Colon LE, Johnson LA, Gottschalk RW. Comparing clobetasol propionate 0.05% spray to calcipotriene 0.005% betamethasone dipropionate 0.064% ointment for the treatment of moderate to severe plaque psoriasis. Journal of Drugs in Dermatology: JDD. 2009;8(1):52–57. [PubMed: 19180896]
45.: Thawornchaisit P, Harncharoen K. A comparative study of tar and betamethasone valerate in chronic plaque psoriasis: a study in Thailand. Journal of the Medical Association of Thailand. 2007;90(10):1997–2002. [PubMed: 18041415]
46.: Buckley C, Hoffmann V, Shapiro J, Saari S, Cambazard F, Milsgaard M. Calcipotriol plus betamethasone dipropionate scalp formulation is effective and well tolerated in the treatment of scalp psoriasis: a phase II study. Dermatology. 2008;217(2):107–113. [PubMed: 18463448]
47.: Franz TJ, Parsell DA, Halualani RM, Hannigan JF, Kalbach JP, Harkonen WS. Betamethasone valerate foam 0.12%: a novel vehicle with enhanced delivery and efficacy. International Journal of Dermatology. 1999;38(8):628–632. [PubMed: 10487457]
48.: Green C, Ganpule M, Harris D, Kavanagh G, Kennedy C, Mallett R, et al. Comparative effects of calcipotriol (MC903) solution and placebo (vehicle of MC903) in the treatment of psoriasis of the scalp. British Journal of Dermatology. 1994;130(4):483–487. [PubMed: 8186114]
49.: Jarratt M, Breneman D, Gottlieb AB, Poulin Y, Liu Y, Foley V. Clobetasol propionate shampoo 0.05%: a new option to treat patients with moderate to severe scalp psoriasis. Journal of Drugs in Dermatology: JDD. 2004;3(4):367–373. [PubMed: 15303780]
50.: Jemec GB, Ganslandt C, Ortonne JP, Poulin Y, Burden AD, de Unamuno P, et al. A new scalp formulation of calcipotriene plus betamethasone compared with its active ingredients and the vehicle in the treatment of scalp psoriasis: a randomized, double-blind, controlled trial. Journal of the American Academy of Dermatology. 2008;59(3):455–463. [PubMed: 18694678]
51.: Kragballe K, Hoffmann V, Ortonne JP, Tan J, Nordin P, Segaert S. Efficacy and safety of calcipotriol plus betamethasone dipropionate scalp formulation compared with calcipotriol scalp solution in the treatment of scalp psoriasis: a randomized controlled trial. British Journal of Dermatology. 2009;161(1):159–166. [PubMed: 19416259]
52.: Olsen EA, Cram DL, Ellis CN, Hickman JG, Jacobson C, Jenkins EE, et al. A double-blind, vehicle-controlled study of clobetasol propionate 0.05% (Temovate) scalp application in the treatment of moderate to severe scalp psoriasis. Journal of the American Academy of Dermatology. 1991;24(3):443–447. [PubMed: 2061442]
53.: Reygagne P, Mrowietz U, Decroix J, de Waard-van der Spek FB, Acebes LO, Figueiredo A, et al. Clobetasol propionate shampoo 0.05% and calcipotriol solution 0.005%: a randomized comparison of efficacy and safety in subjects with scalp psoriasis. Journal of Dermatological Treatment. 2005;16(1):31–36. [PubMed: 15897165]
54.: Tyring SK, Mendoza N, Appell M, Bibby A, Foster R, Hamilton T, et al. A calcipotriene/betamethasone dipropionate two-compound scalp formulation in the treatment of scalp psoriasis in Hispanic/Latino and Black/African American patients: Results of the randomized, 8-week, double-blind phase of a clinical trial. International Journal of Dermatology. 2010;49(11):1328–1333. [PubMed: 20964660]
55.: van de Kerkhof PC, Hoffmann V, Anstey A, Barnes L, Bolduc C, Reich K, et al. A new scalp formulation of calcipotriol plus betamethasone dipropionate compared with each of its active ingredients in the same vehicle for the treatment of scalp psoriasis: a randomized, double-blind, controlled trial. British Journal of Dermatology. 2009;160(1):170–176. [PubMed: 19067709]
56.: Franz TJ, Parsell DA, Myers JA, Hannigan JF. Clobetasol propionate foam 0.05%: a novel vehicle with enhanced delivery. International Journal of Dermatology. 2000;39(7):535–538. [PubMed: 10940121]
57.: Klaber MR, Hutchinson PE, Pedvis-Leftick A, Kragballe K, Reunala TL, van de Kerkhof PC, et al. Comparative effects of calcipotriol solution (50 micrograms/ml) and betamethasone 17-valerate solution (1 mg/ml) in the treatment of scalp psoriasis. British Journal of Dermatology. 1994;131(5):678–683. [PubMed: 7999600]
58.: McKinnon C, Klaber MR. Calcipotriol (Dovonex) scalp solution in the treatment of scalp psoriasis: comparative efficacy with 1% coal tar/1% coconut oil/0.5% salicylic acid (Capasal) shampoo, and long-term experience. Journal of Dermatological Treatment. 2000;11(1):21–28.
59.: Sofen H, Hudson CP, Cook-Bolden FE, Preston N, Colon LE, Caveney SW, et al. Clobetasol propionate 0.05% spray for the management of moderate-to-severe plaque psoriasis of the scalp: Results from a randomized controlled trial. Journal of Drugs in Dermatology: JDD. 2011;10(8):885–892. [PubMed: 21818510]
60.: Ashcroft DM, Li Wan Po A, Williams HC, Griffiths CE. Cost-effectiveness analysis of topical calcipotriol versus short-contact dithranol: In the treatment of mild to moderate plaque psoriasis. Pharmacoeconomics. 2000;18(5):469–476. [PubMed: 11151400]
61.: Oh PI, Gupta AK, Einarson TR, Maerov P, Shear NH. Calcipotriol in the treatment of psoriasis of linited sverity: pharacoeconomic evaluation. Journal of Cutaneous Medicine and Surgery. 1997;2(1):7–15.
62.: Bottomley JM, Auland ME, Morais J, Boyd G, Douglas WS. Cost-effectiveness of the two-compound formulation calcipotriol and betamethasone dipropionate compared with commonly used topical treatments in the management of moderately severe plaque psoriasis in Scotland. Current Medical Research and Opinion. 2007;2(8):1887–1901. [PubMed: 17610804]
63.: National Institute for Health and Clinical Excellence. The guidelines manual. London: National Institute for Health and Clinical Excellence; 2009. Available from: http://www.nice.org.uk/aboutnice/howwework/developingniceclinicalguidelines/clinicalguidelinedevelopmentmethods/GuidelinesManual2009.jsp. [PubMed: 27905714]
64.: Schofield J, Grindlay D, Williams H. Skin conditions in the UK: a health needs assessment. Nottingham: Centre of Evidence Based Dermatology, University of Nottingham; 2009.
65.: Dawe RS, Wainwright NJ, Cameron H, Ferguson J. Narrow-band (TL-01) ultraviolet B phototherapy for chronic plaque psoriasis: three times or five times weekly treatment? British Journal of Dermatology. 1998;138(5):833–839. [PubMed: 9666830]
66.: Hallaji Z, Barzegari M, Balighi K, Taheri A, Mansoori P. A comparison of three times vs. five times weekly narrowband ultraviolet B phototherapy for the treatment of chronic plaque psoriasis. Photodermatology, Photoimmunology and Photomedicine. 2010;26(1):10–15. [PubMed: 20070833]
67.: Cameron H, Dawe RS, Yule S, Murphy J, Ibbotson SH, Ferguson J. A randomized, observer-blinded trial of twice vs. three times weekly narrowband ultraviolet B phototherapy for chronic plaque psoriasis. British Journal of Dermatology. 2002;147(5):973–978. [PubMed: 12410709]
68.: van de Kerkhof PC, Van Der Valk PG, Swinkels OQ, Kucharekova M, de Rie MA, de Vries HJ, et al. A comparison of twice-daily calcipotriol ointment with once-daily short-contact dithranol cream therapy: a randomized controlled trial of supervised treatment of psoriasis vulgaris in a day-care setting. British Journal of Dermatology. 2006;155(4):800–807. [PubMed: 16965431]
69.: Curtis L. Unit costs of social health care. Canterbury: Personal Social Services Reseach Unit, University of Kent; 2010. Available from: http://www.pssru.ac.uk/pdf/uc/uc2010/uc2010.pdf.
70.: Department of Health. NHS reference costs 2009–2010. 2011. [Last accessed: 1 August 2011]. Available from: http://www.dh.gov.uk/en/Publicationsandstatistics/Publications/PublicationsPolicyAndGuidance/DH_123459.
71.: Nevitt GJ, Hutchinson PE. Psoriasis in the community: prevalence, severity and patients’ beliefs and attitudes towards the disease. Br J Dermatol. 1996;135(4):533–537. [PubMed: 8915141]
72.: Joint Formulary Committee. British national formulary (BNF). 62nd edition. London: British Medical Association and The Royal Pharmaceutical Society of Great Britain; 2011. Available from: http://www.bnf.org.uk.
73.: Fleming C, Ganslandt C, Leese GP. Short- and long-term safety assessment of a two-compound ointment containing calcipotriene/betamethasone dipropionate (Taclonex/Daivobet/Dovobet ointment): hypothalamic-pituitary-adrenal axis function in patients with psoriasis vulgaris. Journal of Drugs in Dermatology: JDD. 2010;9(8):969–974. [PubMed: 20684147]
74.: Richards HL, Fortune DG, Griffiths CE. Adherence to treatment in patients with psoriasis. Journal of the European Academy of Dermatology and Venereology: JEADV. 2006;20(4):370–379. [PubMed: 16643132]
75.: Lloyd A, Swinburn P, Edson E, Bowman L, Boye KS, Janssen B, et al. Development of the EQ-5D-Psoriasis; 27th Scientific Plenary Meeting of the EuroQol Group - Proceedings; 2010. p. 242.
76.: Affleck AG, Bottomley JM, Auland ME, Jackson P, Ryttov J. Cost effectiveness of the two-compound formulation calcipotriol and betamethasone dipropionate gel in the treatment of scalp psoriasis in Scotland. Current Medical Research and Opinion. 2011;27(1):269–284. [PubMed: 21142836]
77.: Jemec GB, van de Kerkhof PC, Enevold A, Ganslandt C. Significant one week efficacy of a calcipotriol plus betamethasone dipropionate scalp formulation. Journal of the European Academy of Dermatology and Venereology. 2011;25(1):27–32. [PubMed: 20456557]
78.: Bottomley JM, Taylor RS, Ryttov J. The effectiveness of two-compound formulation calcipotriol and betamethasone dipropionate gel in the treatment of moderately severe scalp psoriasis: A systematic review of direct and indirect evidence. Current Medical Research and Opinion. 2011;27(1):251–268. [PubMed: 21142838]
79.: National Institute for Health and Clinical Excellence. Etanercept and efalizumab for the treatment of adults with psoriasis, NICE technology appraisal 103. London: National Institute for Health and Clinical Excellence; 2006. Available from: http://guidance.nice.org.uk/TA103.
80.: National Institute for Health and Clinical Excellence. Infliximab for the treatment of adults with psoriasis, NICE technology appraisal 134. London: National Institute for Health and Clinical Excellence; 2008. Available from: http://www.nice.org.uk/TA134.
81.: National Institute for Health and Clinical Excellence. Adalimumab for the treatment of adults with psoriasis, NICE technology appraisal 146. London: National Institute for Health and Clinical Excellence; 2008. Available from: http://guidance.nice.org.uk/TA146.
82.: National Institute for Health and Clinical Excellence. Ustekinumab for the treatment of adults with moderate to severe psoriasis, NICE technology appraisal 180. London: National Institute for Health and Clinical Excellence; 2009. Available from: http://guidance.nice.org.uk/TA180.
83.: National Institute for Health and Clinical Excellence. Guide to the methods of technology appraisal. London: National Institute for Health and Clinical Excellence; 2008. Available from: http://www.nice.org.uk/media/B52/A7/TAMethodsGuideUpdatedJune2008.pdf.
84.: Woolacott N, Hawkins N, Mason A, Kainth A, Khadjesari Z, Vergel YB, et al. Etanercept and efalizumab for the treatment of psoriasis: a systematic review. Health Technology Assessment. 2006;10(46):1–252. [PubMed: 17083854]
85.: Joint Formulary Committee. British national formulary (BNF). 59th edition. London: British Medical Association and The Royal Pharmaceutical Society of Great Britain; 2010. Available from: http://bnf.org/bnf/bnf/current/index.htm.
86.: Chalmers R, Kirby B, Smith A, Burrows P, Little R, Horan M, et al. Replacement of routine liver biopsy by procollagen III aminopeptide for monitoring patients with psoriasis receiving long-term methotrexate: a multicentre audit and health economic analysis. British Journal of Dermatology. 2005;152(3):444–450. [PubMed: 15787812]
87.: Driessen RJ, Bisschops LA, Adang EM, Evers AW, van de Kerkhof PC, de Jong EM. The economic impact of high-need psoriasis in daily clinical practice before and after the introduction of biologics. British Journal of Dermatology. Netherlands. 2010;162(6):1324–1329. [PubMed: 20163420]
88.: Woods AL, Rutter KJ, Gardner LS, Lewis VJ, Saxena S, George SA, et al. Inpatient management of psoriasis: a multicentre service review to establish national admission standards. British Journal of Dermatology. 2008;158(2):266–272. [PubMed: 18067482]
89.: Fonia A, Jackson K, Lereun C, Grant DM, Barker JNWN, Smith CH. A retrospective cohort study of the impact of biologic therapy initiation on medical resource use and costs in patients with moderate to severe psoriasis. British Journal of Dermatology. 2010;163(4):807–816. [PubMed: 20662837]
90.: Department of Health. NHS reference costs 2003 and national tariff 2004 (‘payment by results core tools 2004’). 2004. [Last accessed: 23 November 2004]. Available from: http://www.dh.gov.uk/PublicationsAndStatistics/Publications/PublicationsPolicyAndGuidance/PublicationsPolicyAndGuidanceArticle/fs/en?CONTENT_ID=4070195&chk=UzhHA3.
91.: Department of Health. Hospital episode statistics England: financial year 2002–03. 2003. [Last accessed: 12 December 2004]. Available from: http://www.dh.gov.uk/assetRoot/04/06/74/03/04067403.pdf.
92.: Laws PM, Downs AM, Parslew R, Dever B, Smith CH, Barker JN, et al. Practical experience of Ustekinumab in the treatment of psoriasis: experience from a multicentre, retrospective case cohort study across the U.K. and Ireland. British Journal of Dermatology. 2012;166(1):189–195. [PubMed: 21929536]
93.: Papp K, Ho V, Teixeira HD, Guerette K, Chen K, Lynde C. Efficacy and safety of adalimumab when added to inadequate therapy for the treatment of psoriasis: results of PRIDE, an open-label, multicentre, phase IIIb study [submitted] Journal of the European Academy of Dermatology and Venereology. 2011. Epub. [PubMed: 22023702]
94.: Griffiths CE, Strober BE, van de Kerkhof PC, Ho V, Fidelus-Gort R, Yeilding N, et al. Comparison of ustekinumab and etanercept for moderate-to-severe psoriasis. New England Journal of Medicine. 2010;362(2):118–128. [PubMed: 20071701]

Apart from any fair dealing for the purposes of research or private study, criticism or review, as permitted under the Copyright, Designs and Patents Act, 1988, no part of this publication may be reproduced, stored or transmitted in any form or by any means, without the prior written permission of the publisher or, in the case of reprographic reproduction, in accordance with the terms of licences issued by the Copyright Licensing Agency in the UK. Enquiries concerning reproduction outside the terms stated here should be sent to the publisher at the UK address printed on this page.

The use of registered names, trademarks, etc. in this publication does not imply, even in the absence of a specific statement, that such names are exempt from the relevant laws and regulations and therefore for general use.

The rights of National Clinical Guideline Centre to be identified as Author of this work have been asserted by them in accordance with the Copyright, Designs and Patents Act, 1988.

Bookshelf ID: NBK327704

Contents

< PrevNext >

PubReader
Print View
Cite this Page
National Clinical Guideline Centre (UK). Psoriasis: Assessment and Management of Psoriasis. London: Royal College of Physicians (UK); 2012 Oct. (NICE Clinical Guidelines, No. 153.) Appendix U, References for appendices J – S.
PDF version of this title (11M)